EIVAZI ZIAEI J, ASVADI KERMANI I. USE OF MYELOPEROXIDASE INDEX AS A SUITABLE TOOL TO MONITOR RESPONSE TO THERAPY IN PATIENTS WITH MEGALOBLASTIC ANEMIA. Med J Islam Repub Iran 2005; 18 (4) :303-307
URL:
http://mjiri.iums.ac.ir/article-1-611-en.html
From Shahid Ghazi Hematology Oncology Research Department, Tabriz University of Medical Sciences, Tabriz, Iran. , jziaei@hotmail.com
Abstract: (4938 Views)
Repeated bone marrow examination was found to be of value in assessing response
to treatment in megaloblastic anemia. The objective of this study was monitoring
the response of megaloblastics to treatment, concerning the location of neutrophilic
myeloperoxidase and myeloperoxidase index (MPXI) and their variation in megaloblastic
erythroid progeny. It is possible to follow up megaloblastic cases using a
Technicon HI (Bayer) automated cell counter. Complete blood counts (CBC) of 50
patients whose bone marrow aspirations revealed megaloblastic state and subsequently
responded to treatment with B 12 and folate were studied through pre- and post-treatment
measurements. MPXI level in 41 patients was above normal range (normal: -10
to + 10). Nine patients had normal MPXI, though mean cell volume (MCV) was higher
than 100 fL. The highest value of MPXI was 41.5 .The mean values of MPXI were
18.3 and 2.05 in pre- and post-treatment measurements respectively. MPXIs were
decreased after treatment in 92% of patients (p= 0.008). According to this investigation,
the MPXI measurement is a suitable test in monitoring the response for treatment.